Urinary Tract Infections Clinical Trial
— PRUVEOfficial title:
Mechanisms of Successful Vaginal Estrogen Prophylaxis for Postmenopausal Women With Recurrent Urinary Tract Infections: Urogenital Microbiota and Host Immune Responses
Verified date | October 2023 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Among postmenopausal women who suffer from recurrent urinary tract infections (UTI), vaginal estrogen therapy prevents UTI recurrences for 50% of sufferers. This research will investigate why some women benefit but others do not, focusing on (a) the effects of vaginal estrogen therapy on the bacteria that inhabit the vagina and bladder, (b) its influence on immune responses in both compartments, and (c) the extent to which those changes are critical to successful UTI prevention. The findings will be a first step in the development of more effective strategies to prevent UTI, one of the most common and costly benign urologic conditions.
Status | Enrolling by invitation |
Enrollment | 50 |
Est. completion date | August 31, 2025 |
Est. primary completion date | August 31, 2025 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 55 Years to 100 Years |
Eligibility | Inclusion Criteria: Participants in this study will be - Postmenopausal women (menopausal for at least 1 year) - Minimum age of 55 years - Participants will have documentation of recurrent UTI, defined as follows: - History of treatment for at least 3 UTIs in the past year or 2 episodes within 6 months AND - At least one positive urine culture during an acute symptomatic episode. Exclusion Criteria: - Women receiving antibiotic prophylaxis to prevent UTI recurrence; - Women with contraindications to vaginal estrogen (as indicated on the FDA-mandated package insert) and those who have used vaginal or systemic estrogen within the past 6 months; - Women with an active UTI and those who have received antibiotics within the prior 2 weeks; - Women with complicated rUTI, defined by immune compromise, anatomic or functional abnormalities of the urinary tract, indwelling catheterization, those performing self-catheterization, and those with neurological disease or illness relevant to the lower urinary tract; - Women with only asymptomatic bacteriuria (rather than recurrent symptomatic UTI) |
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins Bayview Medical Center | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Maryland |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Vaginal microbiota | Changes to relative vaginal abundance of key Lactobacillus spp. before and after treatment. | Baseline and 12 weeks | |
Primary | Change in Vaginal Interleukin-6 level | Changes to vaginal Interleukin-6 before and after treatment. | Baseline and 12 weeks | |
Primary | Change in Urinary microbiota | Changes to relative urinary abundance of key Lactobacillus spp. before and after treatment. | Baseline and 12 weeks | |
Primary | Change in Urinary Interleukin-6 level | Changes to urinary Interleukin-6 before and after treatment. | Baseline and 12 weeks | |
Secondary | Urinary tract infection recurrence | Occurrence of symptomatic UTI after at least 12 weeks of therapy. | Weeks 12 to 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04495699 -
Asymptomatic Renal Calculi in Recurrent Urinary Tract Infections
|
||
Terminated |
NCT05254808 -
EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care
|
Phase 3 | |
Completed |
NCT03680612 -
Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI
|
Phase 2 | |
Completed |
NCT03282006 -
Treating Pyelonephritis an Urosepsis With Pivmecillinam
|
Phase 4 | |
Completed |
NCT03526484 -
The Utility of Urinalysis Prior to In-Office Procedures
|
N/A | |
Completed |
NCT05397782 -
Effects of Flourish on Recurrent Urinary Tract Infection
|
N/A | |
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03687255 -
Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections
|
Phase 3 | |
Recruiting |
NCT05227937 -
Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
|
||
Completed |
NCT02864420 -
Hospitalization at Home: The Acute Care Home Hospital Program for Adults
|
N/A | |
Completed |
NCT03131609 -
Avoiding Bacterial Contamination of Clean Catch Urine Cultures in Ambulatory Patients in the Emergency Department
|
||
Completed |
NCT01911143 -
A Retrospective, Blinded Validation of a Host-response Based Diagnostics
|
N/A | |
Completed |
NCT01333254 -
A Trial of Different Methods for Bladder Drainage in Hip Surgery Patients
|
N/A | |
Terminated |
NCT00594594 -
Adjuntive Probiotic Therapy in Treating Urinary Tract Infections in Spinal Cord Injury
|
Phase 1 | |
Completed |
NCT00216853 -
A Study of Vaginal MicroFlora and Immune Profiles of Patients With Recurrent Urinary Tract Infection
|
N/A | |
Completed |
NCT00787085 -
The Significance of Funguria in Hospitalized Patients
|
N/A | |
Completed |
NCT05719753 -
The Effectiveness of a Bacteriophobic Coating on Urinary Catheters
|
N/A | |
Recruiting |
NCT05415865 -
The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder
|
Phase 3 | |
Not yet recruiting |
NCT05880329 -
DIagnoSing Care hOme UTI Study
|
||
Recruiting |
NCT04615065 -
Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
|